PMI — Picard Medical Income Statement
0.000.00%
Last trade - 00:00- $703.71m
- $745.25m
- $4.39m
Annual income statement for Picard Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 4.11 | 5.04 | 4.39 |
| Cost of Revenue | |||
| Gross Profit | -4.99 | -2.7 | -0.112 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 15.2 | 20.5 | 18.1 |
| Operating Profit | -11.1 | -15.5 | -13.7 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -11.2 | -15.6 | -21.1 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -11.2 | -15.6 | -21.1 |
| Net Income Before Extraordinary Items | |||
| Net Income | -11.2 | -15.6 | -21.1 |
| Adjustments to Net Income | |||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -12.7 | -18 | -23.7 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.175 | -0.249 | -0.329 |